Difference between revisions of "Nadroparin (Fraxiparine)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "8 PubMed" to "8/ PubMed") |
m |
||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your pråeferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your pråeferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. | ||
| + | ==History of changes in Health Canada indication== | ||
| + | *1997-11-27: Initial notice of compliance. | ||
==Also known as== | ==Also known as== | ||
*'''Brand names:''' Fraxiparine, Fraxodi | *'''Brand names:''' Fraxiparine, Fraxodi | ||
| Line 21: | Line 23: | ||
[[Category:Venous thromboembolism medications]] | [[Category:Venous thromboembolism medications]] | ||
| − | [[Category:Health Canada approved | + | [[Category:Health Canada approved in 1997]] |
Latest revision as of 00:00, 17 June 2023
General information
Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your pråeferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
History of changes in Health Canada indication
- 1997-11-27: Initial notice of compliance.
Also known as
- Brand names: Fraxiparine, Fraxodi
References
- Cancer-DACUS: Napolitano M, Saccullo G, Malato A, Sprini D, Ageno W, Imberti D, Mascheroni D, Bucherini E, Gallucci P, D'Alessio A, Prantera T, Spadaro P, Rotondo S, Di Micco P, Oriana V, Urbano O, Recchia F, Ghirarduzzi A, Lo Coco L, Mancuso S, Casuccio A, Rini GB, Siragusa S. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. J Clin Oncol. 2014 Nov 10;32(32):3607-12. Epub 2014 Sep 29. link to original article PubMed